PDCD1 and Hodgkins lymphoma: (204) evaluated the efficacy of PD-1 monotherapy and PD-1 combined with DNA methyltransferase inhibitor (decitabine) in patients with relapsed/refractory classical Hodgkin’s lymphoma.